These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30578762)

  • 1. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
    Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
    Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal Cancer CTCs Detection Using Two FCM Protocol Approaches.
    Mourtzikou A; Stamouli M; Karakitsos P; Athanasas G
    Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
    Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
    World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
    Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
    Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
    Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of CD133
    Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Hu J; Li Y; Mo X; Zhou Z
    Cancer Med; 2017 Dec; 6(12):2850-2857. PubMed ID: 29105339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
    Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
    Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
    Sastre J; Maestro ML; Puente J; Veganzones S; Alfonso R; Rafael S; García-Saenz JA; Vidaurreta M; Martín M; Arroyo M; Sanz-Casla MT; Díaz-Rubio E
    Ann Oncol; 2008 May; 19(5):935-8. PubMed ID: 18212090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.
    Lu Y; Liang H; Yu T; Xie J; Chen S; Dong H; Sinko PJ; Lian S; Xu J; Wang J; Yu S; Shao J; Yuan B; Wang L; Jia L
    Cancer; 2015 Sep; 121(17):3036-45. PubMed ID: 25945459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients.
    de Albuquerque A; Kubisch I; Ernst D; Breier G; Stamminger G; Fersis N; Stölzel U; Boese-Landgraf J; Eichler A; Kaul S
    Clin Lab; 2012; 58(5-6):373-84. PubMed ID: 22783565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.